Abstract
It has been proposed that diabetes was associated with an increased risk of cancer mortality and morbidity. Complex mechanisms are involved in the association between diabetes and cancer. Metformin has been suggested to reduce the risk of cancer incidence (Hazard ratio 0.63 (95% CI 0.53- 0.75)) or cancer mortality (Hazard ratio 0.43 (95% CI 0.23-0.80)), but insulin or sulfonylurea is suspected to increase the risk of cancer incidence (Hazard ratio 1.36 (95% CI 1.19-1.54)) or cancer mortality (Hazard ratio 1.30 (95% CI 1.10-1.60)). Evidences on these issues are reviewed and summarized in this chapter.
Keywords: Diabetes, anti-diabetic drugs, cancer motality and morbidity.
Related Journals
Current Dentistry
Current Traditional Medicine
Adolescent Psychiatry
New Emirates Medical Journal
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents
Endocrine, Metabolic & Immune Disorders - Drug Targets
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)
Current Diabetes Reviews
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Recent Advances in Anesthesiology
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents